ENCINITAS, California, USA & WROCLAW, Poland – June 8, 2026
Vasa Therapeutics, a clinical-stage biotechnology company focused on therapies targeting cardiovascular and metabolic aging, has announced two scientific presentations featuring its lead investigational candidate VS-041 at the upcoming ECM2026 Extracellular Matrix Pharmacology Conference in Copenhagen, Denmark. The presentations will showcase new preclinical efficacy data, first-in-human clinical findings, and the design of an ongoing Phase 1c proof-of-mechanism trial evaluating VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF). The data highlight the potential of a novel therapeutic approach designed to address the underlying extracellular matrix (ECM) remodeling and myocardial fibrosis that contribute to disease progression in HFpEF, a condition affecting millions of patients worldwide and currently lacking effective disease-modifying therapies. By targeting key biological drivers of cardiovascular aging, Vasa aims to advance a first-in-class precision medicine strategy capable of transforming treatment outcomes in one of the most challenging areas of cardiovascular medicine.
VS-041 Targets Fibrosis and Cardiac Stiffening in HFpEF
At the center of the company’s presentations is VS-041, a first-in-class, oral narrow-spectrum matrix metalloproteinase (MMP) inhibitor designed to address pathological extracellular matrix remodeling. Unlike conventional therapies that primarily manage symptoms, VS-041 is intended to directly target the biological mechanisms responsible for myocardial fibrosis and cardiac stiffening, two hallmark features of HFpEF. Preclinical studies have demonstrated that the investigational therapy significantly reduced cardiac fibrosis and improved diastolic heart function in validated disease models. Researchers also observed inhibition of endotrophin release from primary human cardiac fibroblasts, further supporting the compound’s potential role in modifying disease progression.
These findings suggest that VS-041 could represent a new therapeutic class focused on reversing structural cardiac changes associated with aging-related heart failure rather than simply alleviating symptoms. Given the growing prevalence of HFpEF and the limited availability of disease-modifying treatments, the development of novel fibrosis-targeting approaches has become a major priority in cardiovascular drug research.
Clinical Data and Phase 1c Trial Advance Development Strategy
Advertisement
The ECM2026 presentations will also highlight encouraging results from Vasa’s first-in-human clinical development program. According to the company, VS-041 demonstrated a favorable safety and tolerability profile in Phase 1 single and multiple ascending dose studies, successfully translating preclinical safety observations into human subjects. These findings have supported the initiation of an ongoing Phase 1c proof-of-mechanism trial, which is designed to evaluate the compound’s biological effects on extracellular matrix remodeling and fibrosis-related pathways in patients with HFpEF.
Researchers will present the scientific rationale behind the study, along with details regarding biomarker selection and clinical endpoints. Importantly, VS-041 has received Fast Track designation from the U.S. Food and Drug Administration (FDA), recognizing its potential to address a significant unmet medical need in heart failure. The designation may facilitate accelerated development and regulatory interactions as the program advances toward later-stage clinical evaluation.
ECM Biology Opens New Opportunities in Cardiovascular Medicine
The upcoming ECM2026 conference brings together leading researchers, clinicians, and biotechnology innovators focused on translating extracellular matrix science into new therapies. Vasa’s participation reflects growing scientific interest in fibrosis and ECM remodeling as critical drivers of chronic disease. Fibrogenesis is estimated to contribute to approximately 40% of deaths across the Western world, yet effective anti-fibrotic therapies remain limited across multiple disease areas. By focusing on extracellular matrix biology and cardiovascular aging, Vasa is positioning itself at the forefront of a rapidly emerging field of therapeutic innovation.
Beyond HFpEF, the company believes its platform may have broader applications in related fibroinflammatory conditions, including chronic kidney disease and other age-associated disorders. As precision medicine increasingly shifts toward targeting underlying disease mechanisms, the VS-041 program represents a promising effort to redefine treatment strategies for patients with chronic cardiovascular disease and potentially establish a new standard of care for fibrosis-driven conditions.
Source: Vasa Therapeutics press release
